Licensing · GCC · Announced 24 Dec 2024
Bio-Thera Solutions → Tabuk Pharmaceuticals
Licensing deal between Bio-Thera Solutions (China) and Tabuk Pharmaceuticals (Saudi Arabia), covering Ustekinumab, announced 24 Dec 2024. Value: Undisclosed.
Parties: Bio-Thera Solutions, Ltd. (China) → TABUK PHARMACEUTICALS (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia Only
- Therapeutic area
- Immunology / Inflammation
- Asset
- Ustekinumab
- Announced
- 24 Dec 2024
Our analysis
Why this matters.
In December 2024, Bio-Thera granted T abuk Pharmaceuticals — an Astra Industrial Group company — exclusive Saudi rights to BAT2206, its biosimilar to J&J's Stelara (ustekinumab), a former ~$10bn-a-year immunology blockbuster spanning psoriasis, psoriatic arthritis and inflammatory bowel disease.
The full analysis is free to read with a work email on this page.
Source: Pearce IP